Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.

Inflammatory bowel disease (IBD) Mayo endoscopic score (MES) Mucosal healing (MH) Steroid-free clinical remission Ulcerative colitis (UC)

Journal

BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547

Informations de publication

Date de publication:
03 Mar 2022
Historique:
received: 18 09 2021
accepted: 10 02 2022
entrez: 4 3 2022
pubmed: 5 3 2022
medline: 8 3 2022
Statut: epublish

Résumé

Mucosal healing (MH) evaluated by endoscopy is a novel target of therapy in UC as it is associated with improved long-term outcomes. It is defined based on the Mayo endoscopic score (MES), but it is still to define whether a value of MES 0 or 1 should be the target. The purpose of this paper is to present the results of a systematic review with meta-analysis which compares long-term outcomes of patients in steroid-free clinical remission with MES 0 with those with MES 1. A systematic electronic search of the literature was performed using Medline, Scopus, and CENTRAL through December 2020 (PROSPERO n:CRD42020179333). The studies concerned UC patients, in steroid-free clinical remission, with MES of 0 or 1, and with at least 12-months of follow-up. Out of 4611 citations, 15 eligible studies were identified. Increases in clinical relapse among patients with MES 1 were observed in all the studies included in this review, suggesting that MES of 1 have a higher risk of relapse than a score of 0. MES 0 patients displayed a lower risk of clinical relapse (OR 0.33; 95% CI 0.26-0.43; I MES 0 is associated with a lower rate of clinical relapse than is MES 1. For this reason, MES 0, rather than MES 0-1, should be considered the therapeutic target for patients with UC.

Sections du résumé

BACKGROUND BACKGROUND
Mucosal healing (MH) evaluated by endoscopy is a novel target of therapy in UC as it is associated with improved long-term outcomes. It is defined based on the Mayo endoscopic score (MES), but it is still to define whether a value of MES 0 or 1 should be the target. The purpose of this paper is to present the results of a systematic review with meta-analysis which compares long-term outcomes of patients in steroid-free clinical remission with MES 0 with those with MES 1.
METHODS METHODS
A systematic electronic search of the literature was performed using Medline, Scopus, and CENTRAL through December 2020 (PROSPERO n:CRD42020179333). The studies concerned UC patients, in steroid-free clinical remission, with MES of 0 or 1, and with at least 12-months of follow-up.
RESULTS RESULTS
Out of 4611 citations, 15 eligible studies were identified. Increases in clinical relapse among patients with MES 1 were observed in all the studies included in this review, suggesting that MES of 1 have a higher risk of relapse than a score of 0. MES 0 patients displayed a lower risk of clinical relapse (OR 0.33; 95% CI 0.26-0.43; I
CONCLUSIONS CONCLUSIONS
MES 0 is associated with a lower rate of clinical relapse than is MES 1. For this reason, MES 0, rather than MES 0-1, should be considered the therapeutic target for patients with UC.

Identifiants

pubmed: 35240984
doi: 10.1186/s12876-022-02157-5
pii: 10.1186/s12876-022-02157-5
pmc: PMC8895505
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

92

Informations de copyright

© 2022. The Author(s).

Références

Inflamm Bowel Dis. 2014 Feb;20(2):231-9
pubmed: 24351660
Aliment Pharmacol Ther. 2011 Jul;34(2):113-24
pubmed: 21615435
Am J Gastroenterol. 2019 Dec;114(12):1922-1923
pubmed: 31658106
Clin Gastroenterol Hepatol. 2016 Sep;14(9):1245-1255.e8
pubmed: 26829025
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Endosc Int Open. 2019 Apr;7(4):E568-E575
pubmed: 30957007
Inflamm Bowel Dis. 2021 Jan 19;27(2):207-214
pubmed: 32170946
J Am Med Assoc. 1951 Oct 6;147(6):541-9
pubmed: 14873501
J Crohns Colitis. 2016 Jan;10(1):13-9
pubmed: 26351390
Lancet Gastroenterol Hepatol. 2021 Feb;6(2):139-148
pubmed: 33189181
Gastroenterology. 2004 Feb;126(2):451-9
pubmed: 14762782
Am J Gastroenterol. 2019 May;114(5):733-745
pubmed: 30694863
World J Gastroenterol. 2013 Feb 21;19(7):968-78
pubmed: 23467585
Gastrointest Endosc. 2018 Dec;88(6):887-898
pubmed: 30142351
Cochrane Database Syst Rev. 2018 Jan 16;1:CD011450
pubmed: 29338066
Inflamm Bowel Dis. 2017 Dec;23(12):2238-2244
pubmed: 28991857
Scand J Gastroenterol. 2016 Sep;51(9):1069-74
pubmed: 26895215
Intest Res. 2016 Jan;14(1):37-42
pubmed: 26884733
Eur J Intern Med. 2011 Dec;22(6):621-5
pubmed: 22075292
Gastroenterology. 2020 Oct;159(4):1262-1275.e7
pubmed: 32585306
Dig Dis Sci. 1994 Jul;39(7):1550-7
pubmed: 8026269
Therap Adv Gastroenterol. 2017 Oct;10(10):749-759
pubmed: 29051786
Expert Rev Gastroenterol Hepatol. 2014 Feb;8(2):139-45
pubmed: 24417262
J Crohns Colitis. 2016 Jan;10(1):20-5
pubmed: 26438714
Am J Gastroenterol. 2016 Dec;111(12):1692-1701
pubmed: 27725645
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Intest Res. 2018 Jan;16(1):55-61
pubmed: 29422798
Am J Gastroenterol. 2019 Mar;114(3):384-413
pubmed: 30840605
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
Aliment Pharmacol Ther. 2010 Oct;32(8):984-9
pubmed: 20937043
Gastroenterology. 2021 Apr;160(5):1558-1569.e8
pubmed: 33347880
J Clin Epidemiol. 2001 Oct;54(10):1046-55
pubmed: 11576817
Radiology. 1951 Jul;57(1):1-14
pubmed: 14854178
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
United European Gastroenterol J. 2018 Jun;6(5):765-772
pubmed: 30083339
Dig Liver Dis. 2017 Dec;49(12):1327-1331
pubmed: 28958412
Gut. 2016 Mar;65(3):408-14
pubmed: 25986946
Dig Liver Dis. 2013 Dec;45(12):969-77
pubmed: 23932331
Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):915-27
pubmed: 27043489
J Crohns Colitis. 2019 Mar 26;13(3):273-284
pubmed: 30137278
Gastroenterol Res Pract. 2013;2013:192794
pubmed: 23762033
Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):457-9
pubmed: 24654957
Clin Transl Gastroenterol. 2018 Feb 20;9(3):136
pubmed: 29491393
J Dig Dis. 2017 Nov;18(11):634-641
pubmed: 28949435

Auteurs

Angelo Viscido (A)

Gastroenterology Unit, Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi 1, 67100, L'Aquila, Italy. angelo.viscido@univaq.it.

Marco Valvano (M)

Gastroenterology Unit, Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi 1, 67100, L'Aquila, Italy.

Gianpiero Stefanelli (G)

Gastroenterology Unit, Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi 1, 67100, L'Aquila, Italy.

Annalisa Capannolo (A)

Gastroenterology Unit, Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi 1, 67100, L'Aquila, Italy.

Chiara Castellini (C)

Andrology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Eugenia Onori (E)

Internal Medicine and Nephrology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Antonio Ciccone (A)

Gastroenterology and Digestive Endoscopy Unit, ASUR 1, Pesaro, Italy.

Filippo Vernia (F)

Gastroenterology Unit, Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi 1, 67100, L'Aquila, Italy.

Giovanni Latella (G)

Gastroenterology Unit, Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L'Aquila, Piazzale Salvatore Tommasi 1, 67100, L'Aquila, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH